Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors

Entera Bio appointed Dr. Juan Camilo Arjona Ferreira, currently Head of R&D and Chief Medical Officer at Organon, to its Board of Directors effective December 1, 2026, succeeding outgoing director Haya Taitel. He brings two decades of clinical development and regulatory experience in women's health across Organon, Myovant, Shionogi and Merck, which aligns with Entera's lead program EB613 in late-stage development for osteoporosis and EB612 entering early clinical development for hypoparathyroidism.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.